Seymour JF - Search Results

1

Challenges of phase III trial design for novel treatments in diseases with no standard treatment: the AZA-001 myelodysplasia study model.

Fenaux P, Seymour JF, Santini V, Silverman L, Gore S, List A, Sanz G, Mufti GJ, Estey E, Swern AS, Beach CL, Hellstrom-Lindberg E. Fenaux P, et al. Among authors: seymour jf. Leuk Res. 2014 Feb;38(2):258-62. doi: 10.1016/j.leukres.2013.10.014. Epub 2013 Oct 27. Leuk Res. 2014. PMID: 24360612 Free article.

2

Investigation of karyotypic, morphologic and clinical features in patients with acute myeloid leukemia blast cells expressing the neural cell adhesion molecule (CD56).

Seymour JF, Pierce SA, Kantarjian HM, Keating MJ, Estey EH. Seymour JF, et al. Leukemia. 1994 May;8(5):823-6. Leukemia. 1994. PMID: 7514247

3

Response to interferon-alpha in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosine.

Seymour JF, Estey EH, Keating MJ, Kurzrock R. Seymour JF, et al. Leukemia. 1995 May;9(5):929-32. Leukemia. 1995. PMID: 7769859

4

The contribution of Auer rods to the classification and prognosis of myelodysplastic syndromes.

Seymour JF, Estey EH. Seymour JF, et al. Leuk Lymphoma. 1995 Mar;17(1-2):79-85. doi: 10.3109/10428199509051706. Leuk Lymphoma. 1995. PMID: 7773165 Review.

5

2-chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia.

Seymour JF, Kurzrock R, Freireich EJ, Estey EH. Seymour JF, et al. Blood. 1994 May 15;83(10):2906-11. Blood. 1994. PMID: 7910051 Free article.

6

The prognostic significance of auer rods in myelodysplasia.

Seymour JF, Estey EH. Seymour JF, et al. Br J Haematol. 1993 Sep;85(1):67-76. doi: 10.1111/j.1365-2141.1993.tb08647.x. Br J Haematol. 1993. PMID: 8251411

7

Secondary acute myeloid leukemia with inv(16): report of two cases following paclitaxel-containing chemotherapy and review of the role of intensified ara-C therapy.

Seymour JF, Juneja SK, Campbell LJ, Ellims PH, Estey EH, Prince HM. Seymour JF, et al. Leukemia. 1999 Nov;13(11):1735-40. doi: 10.1038/sj.leu.2401552. Leukemia. 1999. PMID: 10557046 Review.

8

Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: a phase II study.

Giles FJ, O'Brien SM, Santini V, Gandhi V, Plunkett W, Seymour JF, Robertson LE, Kantarjian HM, Keating MJ. Giles FJ, et al. Among authors: seymour jf. Leuk Lymphoma. 1999 Dec;36(1-2):57-65. doi: 10.3109/10428199909145949. Leuk Lymphoma. 1999. PMID: 10613450 Clinical Trial.

9

Treatment-related myelodysplasia following fludarabine combination chemotherapy.

Tam CS, Seymour JF, Prince HM, Kenealy M, Wolf M, Januszewicz EH, Westerman D. Tam CS, et al. Among authors: seymour jf. Haematologica. 2006 Nov;91(11):1546-50. Haematologica. 2006. PMID: 17082012

10

Stem cell factor and high-dose twice daily filgrastim is an effective strategy for peripheral blood stem cell mobilization in patients with indolent lymphoproliferative disorders previously treated with fludarabine: results of a Phase II study with an historical comparator.

Herbert KE, Morgan S, Prince HM, Westerman DA, Wolf MM, Carney DA, Yuen K, di Iulio J, Seymour JF. Herbert KE, et al. Among authors: seymour jf. Leukemia. 2009 Feb;23(2):305-12. doi: 10.1038/leu.2008.302. Epub 2008 Nov 6. Leukemia. 2009. PMID: 18987661 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

562 results

Search Page